Key facts
- Theolytics’s last known valuation is $71.0M (Dec 2024).
- It has raised $84.6M; the latest was Grant ($9.4M) in Mar 2026.
- Notable investors include Innovate UK, BGF (Financial Services), University of Oxford, Oxford Science Enterprises, M Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Theolytics
- ·The full record, as it builds
Funding rounds
No funding rounds for Theolytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Theolytics
Developer of a best-in-class oncolytic immunotherapy platform designed to deliver targeted and effective treatments for patients with difficult-to-treat cancers. The company offers a proprietary adenoviral technology optimized for direct and systemic intravenous administration, enabling patients with ovarian, colorectal, and hematological cancers to access more precise and potentially more effective therapeutic options.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2017
- Employees
- 32
- Website
- theolytics.com/
- Ownership
- Privately Held (backing)
Theolytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Theolytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Theolytics in its N-PORT filings yet. We sweep new filings monthly.